INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sinovac Biotech Ltd. Investors
January 06 2017 - 10:30AM
Business Wire
Law Offices of Howard G. Smith announces an investigation
on behalf of investors of Sinovac Biotech Ltd. (“Sinovac” or the
“Company”) (NASDAQ: SVA) concerning the Company and its officers’
potential violation of federal securities laws.
Sinovac is a biopharmaceutical company that engages in the
research, development, manufacture and commercialization of
vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1
and H1N1 pandemic influenza and mumps in the People's Republic of
China.
On December 21, 2016, media outlet SeekingAlpha issued a
report disclosing that Sinovac’s Chairman and CEO, Weidong Ying,
had paid bribes to Yin Hongzhang, the Deputy Director General of
the Center for Drug Evaluation for the China Food and Drug
Administration, to help procure and pass drug applications and
evaluations.
If you purchased Sinovac securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email
to howardsmith@howardsmithlaw.com, or visit our website at
www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170106005085/en/
Law Offices of Howard G. SmithHoward G. Smith,
Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024